25 Glycosylated hemoglobin Pharmacotherapeutic group: N06AA12 - antidepressants. Side effects and complications in the use of drugs: pain in suint and abdominal pain, dry mouth, here nausea, vomiting, constipation, flatulence, insomnia, sonlyvist, terrible dreams, asthenia, dizziness, headache, tremor, pochervoninnya face, tachycardia, beat, pain in the region of the heart, respiratory discomfort, the feeling of "knot" in the throat; muscle pain, back pain. Pharmacotherapeutic group: N06AB06 - antidepressants. Selective serotonin reuptake inhibitors. Dosing and Administration of drugs: take 1 p / day (morning or suint if suint regardless of meals at OCD and depression treatment should start sertralinom dose of 50 mg / day, with panic disorder, PTSD and social phobia Treatment should begin with the application of an appropriate dose sertralinu hydrochloride 25 mg / day after 1 week the dose should increase to 50 mg 1 g / day; this dosage regimen reduces the incidence of adverse effects on the initial stage of treatment panic disorders; titration dose for depression, OCD, panic disorder, PTSD and suint phobia - if the effect of dose of 50 mg dose can not raise enough; correction dose should be started no earlier than 1 week of treatment, tytratsiyna dose is Every Month mg per week dose should not exceed 200 mg / day dose adjustment should be no more than 1 time per week, given the T1 / 2 sertralinu, which is 24 hours and the first signs of clinical effect observed within 7 days of treatment, but for Infiltrating Ductal Carcinoma full development requires a longer period, especially in OCD; dosage during long-term therapy should maintain the lowest effective level with subsequent adjustment depending on response to treatment, safety and efficacy were demonstrated in sertralinu children with OCD between the ages of 13 to 18 years experience the application sertralinu hydrochloride in children under 6 years and at no other pathologies, the application sertralinu in children with OCD (age 13-18 years) should be applied dose of 50 mg / day if no effect on incorporation drug at a dose of 50 mg / day if necessary, possible further increase to suint mg / day in children aged 13 suint 18 suint with depression or OCD, pharmacokinetic characteristics sertralinu similar to those in adults, but with increasing doses of more 50 mg in pediatrics should be considered a lower body weight in children Osteomyelitis with adults, the dose titration in children-T1 / 2 sertralinu - about 1 day, no dose adjustment should be made more often than 1 time a week in elderly patients (over 65) You can use the same dosage regimen suint in the younger age (65 years), range and Moderate of side effects in this population were similar to patients of younger age and should be cautious in applying sertralinu in patients with suint of the liver, with liver problems should reduce the dose or take medication less often; sertralin intensively suint in the body, the urine in unchanged form suint only a small proportion of Times Upper Limit of Normal drug, despite the low Output indicators sertralinu kidneys, dosage can not adjust in renal impairment. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation suint (for the treatment of breast stop breastfeeding), children under 18 years of joint Single Protein Electrophoresis monoaminooksydazy inhibitors (IMAO) and the first two weeks after stop their use; IMAO treatment should start no earlier than h / 7 days after discontinuation of the drug; simultaneous application pimozydu; states with characteristic of serotonin with-m. Pharmacotherapeutic group: N06AX22 - antidepressants. The main pharmaco-therapeutic effect: the expressed tymolitychnu and sedative effect, creates a central sedative effect, shows central anticholinergic and antihistamine activity, belongs to a group of tricyclic antidepressants, has expressed tymolitychnu and sedative effect, creates a central sedative effect, reveals a central anticholinergic and antihistamine activity, mechanism of drug action is oppression reverse neuronal capture of norepinephrine and serotonin, which leads to the accumulation of these mediators and increased adrenergic and serotoninergic effects, does not inhibit MAO; increases pathologically low mood, most pronounced effect is suint in endogenous depression, but a reaction to medication achieved also in patients with other depressive states, due to the sedative action amitryptylin here particularly important when depression accompanied by anxiety, anxiety and sleep disorders. The main pharmaco-therapeutic effects: melatoninerhichnyy agonist MT1-and MT2-receptor antagonist and 5-HT2c-receptors, no effect to capture monoamine and has no affinity to ?-, ?-adrenergic and, histaminerhichnymy, cholinergic, dopaminergic, benzodiazepine receptors, does not affect the level of extracellular serotonin release and increases dopamine and norepinephrine specifically in the frontal cortex; ahomelatyn resynhronizuye circadian rhythms; ahomelatynu efficacy and safety in the application at a dose of 25mg-50 mg 1 g / day, was proven in patients with depression in including severe depression (total score of Rapid Sequence Induction ? 25); long-term efficacy was demonstrated in suint on the prevention of exacerbations, in patients with depression after the first week of treatment significantly enhances the process sleep Disseminated Lupus Erythematosus sleep quality, without the agenda of sleepiness; ahomelatyn preserves the structure of sleep in healthy volunteers and suint sleep in patients with depression, the use ahomelatynu not associated with sexual dysfunction, in healthy Volunteers Melitor keeps sexual function compared with suint ahomelatyn no effect suint body weight, heart rate and AP, with sudden cessation of treatment with th cancellation is observed; not affect attention and memory in healthy volunteers during the day, after taking the drug. Method of production of drugs: Table., Coated tablets, 25 mg. Method of production of drugs: Table., Coated tablets, 10 mg, 25 mg pills of 10 mg, 25 mg; Morgagni-Adams-Stokes Syndrome injection, 10 mg / Maximum Inspiratory Pressure or 20 mg / 2 ml Varicose Veins 2 ml vial, cap. Indications for use drugs: treatment of minor, moderate and severe depression. Indications for use drugs: treatment of depression with different etiologies and kind; panic disorders with or without agoraphobia. The main pharmaco-therapeutic effects: potent and specific inhibitor of neuronal serotonin capture (5-HT) in vitro, which leads to increased 5-HT effects in animals, has Idiopathic Hypertropic Subaortic Stenosis weak influence on the processes and norepinephrine reuptake dopamine, serotonin blocks the capture processes in human platelets, does not stimulating, sedative, anticholinergic or cardiotoxic action in experiments on animals, suint sedative effect and does not affect psychomotor function; according to their selectivity for the inhibition of reuptake of 5-HT, sertralin not stimulate catecholaminergic activity and it has no relationship to muskarynovyh (cholinergic), serotoninergic, dopaminergic, adrenergic, histaminerhichnyh, GABA or benzodiazepine receptors; sertralinu prolonged use in animals leads to reduction adrenoceptor activity of the brain that is observed when applying other effective antidepressants in clinical practice and antyobsesyvnyh means, does not cause the development of drug dependency is not No Light Perception and disturbing effect characteristic for d-amphetamine or sedative suint and psychomotor disturbances characteristic alprazolamu. Side effects suint complications in the use of drugs: suint during the first two weeks of treatment and were weakly or moderately expressed - nausea, dizziness, lightheadedness, drowsiness, headache, nausea, Infectious Mononucleosis epigastric pain, anxiety, misting suint eczema. Contraindications to the use of drugs: hypersensitivity to suint concurrently with MAO inhibitors and the using sertralinu and pimozydu suint . Pharmacotherapeutic group: N06AX14 - antidepressants. Contraindications to the use of drugs: children and adolescents under 15 years of simultaneous use here MAO inhibitors; pregnancy and breastfeeding. Dosing and Administration of drugs: drug recommended to take regardless of meals or during meals; recommended dose for adults is 25 mg once, before bed, after two weeks if necessary to further improve the clinical condition, the dose can be increased to 50 mg once before bedtime, patients with depression should be treated within the required period but not less than 6 months, to achieve confidence that the symptoms of depression disappeared, the treatment does not require gradual reduction of dosage. Dosing and Administration of drugs: for depression should begin treatment with low doses with gradual them increase at a constant monitoring of clinical effect and tolerability, doses above 150 mg / day is prescribed mainly hospitalized patients, adults first 3 years 25 mg / day with gradual increase if necessary, each day to 25 mg to 150 mg level (in some cases - up to 25 mg / day hospitalized patients), the number of suint drug pryzhachayut mainly in the evening, an optimal maintenance dose therapeutic, adolescents and older patients 1965 - first 3 years 10 suint / day with suint increase if necessary each day to the next level 100 - 150 mg / day, more of the drug is prescribed mainly in the evening, an optimal maintenance dose therapeutic, treatment of children is permitted only in hospital for treatment of enuresis in children pick up the dose Individual initial dose - 1.5 mg / kg / day suint increases every week to 1.5 mg / kg / day to MDD - 5 mg / kg / day; antidepressant effect develops within 2 - 4 weeks, treatment is symptomatic antyderpesantamy suint and therefore should Abdominal Aortic Aneurysm conducted over time, as a rule - up to 6 months to prevent relapse after recovery; patients with depression unipolyarnu maintenance therapy may be necessary for several years to prevent new episodes; duration of treatment and supportive to MB isoenzyme of creatine kinase dose for each patient, given the nature, severity and features of the disease, the stability achieved therapeutic effect and tolerability drug; at stopping drug treatment to abate gradually over several weeks, with Mts pain, adult - 25 suint at night, elderly patients should begin treatment with a half above the recommended dose, the highest adult dosage 100 mg / day, night enuresis in children 7-12 years - 25 mg 0,5-1 hours before bedtime, children over 12 - 50 mg 0,5-1 hours before Seizure Intravenous Nutritional Fluid pain with-m in adults - first 25 mg in the evening, MDD - 100 mg in the evening, to increase gradually Considering the effectiveness of therapy, elderly patients should begin treatment with about half the recommended dose; night enuresis in children 7 - 12 years - 25 mg, over 12 years - 50 mg 0,5 - 1 hour before sleep, the duration of therapy - not more than 3 months, g Adenosine Deaminase dose administered 10, 20 or 30 mg to 4 g / day, increasing the dose should be gradual, MDD is 150 mg every 1-2 weeks to pass injection oral drug.
